As with NF1 mutations [23,24], KRAS mutations increase tumor-promoting immune cell function in the TME [31,32], which suggests these compounds offer a promising new therapeutic strategy for PNF and MPNST [33]. This evidence concerns the gene NF1 and neoplasm.